Image For Activity Cover
Interdisciplinary Cancer Team Series Module 2: A Multi-Institutional Review of Contralateral Axillary Metastases: Time for Reclassification as a Local-Regional Event (2023)
Activity Overview

This episode of SurgOnc Today®, features guest faculty, Astrid Botty Van Den Bruele, MD, and Meghan Flanagan, MD, MPH. In a contemporary group of patients diagnosed with contralateral axillary metastases (CAM), those selected for treatment with presumed curative intent experienced improved OS when compared to stage IV (M1) patients. The current literature, as well as some forthcoming data, adds additional support for re-evaluating the stage IV designation, in favor of N3, and consideration of curative intent treatment in this disease entity.



Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Powered By